Δ-8-tetrahydrocannabinol from cannabidiol extracted from hemp

A composition, comprising a >99% pure Δ8-tetrahydrocannabinol (THC) oil having less than 0.3% Δ9-THC, wherein the >99% pure Δ8-THC oil is a distillate having residual solvent and volatile cannabidiol impurities removed by vacuum distillation, and having high temperature cannabinoid impurities with a non-vacuum boiling point higher than 180° C. removed by wiped film distillation, wherein said distillate is a reaction product of a cannabidiol extract from industrial hemp having less than 0.3% Δ9-THC, wherein the composition is formulated for oral, topical, rectal, parenteral, local, or inhalant use, and is a form selected from the group consisting of as an oil, drop, lotion, balm, pill, tablet, cream, gelatin capsule, capsule, suppository, soft gelatin capsule, gel, foams, powder, ointment, spray, and inhalant, and wherein said topical composition having (i) >99% pure D8-THC oil having less than 0.3% D9-THC, the D8-THC oil at a dosage of 5-14 mg/Kg/day, and (ii) a carrier formulation comprising:

• a self-emulsifying wax, a polyol, a fatty alcohol, a moisturizer, a hydrocarbon moisturizer/occlusive, an emulsifier, an antioxidant, and optionally a fragrance, a stabilizer, a skin conditioner, Aloe Barbadensis Leaf Juice, a surfactant, an anti-inflammatory, and a preservative wherein the self-emulsifying wax is selected from glyceryl stearate and PEG-100 stearate, the polyol is glycerin, the fatty alcohol is cetyl alcohol, the moisturizer is allantoin, the hydrocarbon moisturizer/occlusive is petrolatum, the emulsifier is steareth-21, the antioxidant is tocopheryl acetate, the stabilizer is xanthan gum, the skin conditioner is dipotassium glycyrrhizate, the surfactant is triethanolamine, the anti-inflammatory is bisabolol, and the preservative is disodium EDTA.